![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 16, 13394-13400, April 19, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, November 13, 2001, and in revised form, January 24, 2002
Sorsby's fundus dystrophy (SFD) is an autosomal
dominant degenerative disease of the macula caused by mutations in the
tissue inhibitor of metalloproteinase-3 (TIMP-3) gene. Choroidal
neovascularization is a hallmark of this disease, which closely
resembles the exudative form of age-related macular degeneration.
However, the mechanism by which TIMP-3 mutations induce the disease
phenotype in SFD remains unknown. To address this question we
established human retinal pigment epithelial cell lines
expressing wild type or S156C (Ser156 changed to
cysteine) mutant TIMP-3. S156C TIMP-3 had reduced matrix
metalloproteinase (MMP) inhibitory activity in retinal pigment
epithelial cells and resulted in increased secretion and activation of
gelatinase A and B. The conditioned medium from these cells induced
angiogenesis in "in vivo" chick chorioallantoic membrane assays that could be reversed with recombinant wild type TIMP-3. Our data indicate that the choroidal neovascularization in SFD
may be a result of increased MMP activity, which could lead to the
stimulation of angiogenesis. These results also suggest the potential
therapeutic use of TIMP-3 or synthetic MMP inhibitors in this disease.
Sorsby's fundus dystrophy
(SFD),1 a fully penetrant,
autosomal dominant, degenerative disease of the macula (1), is
manifested by symptoms of night blindness or sudden loss of acuity
usually in the third to fourth decades of life due to submacular
neovascularization (2-5). Clinically, early mid-peripheral drusen and
color vision deficits are found (4, 5). SFD is a relatively rare
disease, but it has generated significant interest because it closely
resembles the exudative or "wet" form of age-related macular
degeneration, the most common cause of blindness in the elderly
population of the western world. SFD is characterized by accumulation
of extracellular deposits (drusen)in Bruch's membrane, the
five-layered sheet of connective tissue that separates the retinal
pigment epithelium (RPE) from the choriocapillaris (6). The predominant
histopathological feature in the eyes of a 63-year-old patient with SFD
was a confluent 30-µm thick, lipid-containing amorphous deposit found
between the basement membrane of the RPE and the inner collagenous
layer of Bruch's membrane (6). This is distinct from the basal linear deposits seen in age-related macular degeneration that consist of
filamentous fine granular material and may represent a thickened basement membrane of the RPE (6). The subretinal deposits in both SFD
and age-related macular degeneration have been shown to be rich in
tissue inhibitor of metalloproteinase-3 (TIMP-3) (7, 8). A serious
complication of SFD is the invasion of the thickened Bruch's membrane
by newly formed, thin-walled vessels derived from the choriocapillaris.
These vessels grow into the subretinal space causing exudative
detachment of the RPE and loss of photoreceptors (5). SFD has been
linked with mutations in the TIMP-3 gene (10-12) with five different
missense mutations and a splice site mutation having been identified to date.
TIMP-3 is a member of a family of endogenous matrix metalloproteinase
(MMP) inhibitors of which there are currently four members (TIMPs
1-4). By virtue of their MMP inhibitory activity, TIMP family members
play a potentially important role in regulating matrix composition and
thereby affect a wide range of physiological processes that include
cell growth, invasion, migration, angiogenesis, transformation, and
apoptosis. Structurally TIMPs have a two-domain structure with each
domain folded into three loops held together by three disulfide bonds
(13). The N-terminal domain contains the highly conserved
CXC motif that is responsible for MMP inhibition. The
C-terminal domain confers specific functions such as binding to
pro-MMPs and, in the case of TIMP-3, has been shown to be partly responsible for the ability to bind to the extracellular matrix (ECM)
(14). However, more recently the ECM binding function has also been
attributed to the N-terminal region (15). With one recent exception,
all mutations associated with SFD change residues in exon 5 (which
encodes the C-terminal domain of the molecule) into cysteines. The
exception involves a truncation that also results in an unpaired
cysteine residue in the C-terminal domain (10). The role of these
mutations in generating the SFD phenotype is unclear.
To study the effects of these mutations in retinal pigment epithelium,
we generated stable RPE cell lines expressing wild type or S156C
(Ser156 changed to cysteine) mutant TIMP-3 and investigated
the effects on RPE functions.
Cell Culture--
ARPE-19 cells (American Type Culture
Collection) were maintained in T75 flasks in filter medium consisting
of Dulbecco's modified Eagle's medium/Ham's F-12 plus 10% fetal
bovine serum (Hyclone). All cultures of ARPE-19 grown on tissue culture
plastic were fed weekly. Cultures were routinely passaged by
dissociation with 0.05% (w/v) trypsin and 0.02% (w/v) EDTA,
tetrasodium salt, followed by replating at a split ratio ranging from
1:3 to 1:6.
Generation and Analysis of Timp-3 Transfectant RPE Cell
Lines--
Wild type (WT)-Timp-3 and
S156C-Timp-3 inserts from human cDNA clones were
fused in-frame with FLAG epitope DYKDDDK at their C-terminal end and
cloned into expression vector pcDNA3.1
(CLONTECH, Palo Alto, CA). ARPE-19 cell lines were
transfected by lipofection (LipofectAMINE reagent, Invitrogen) and
selected in medium containing neomycin (0.5 mg/ml). As a control, cells
were transfected with the vector alone. Conditioned medium, lysate, and
ECM samples were prepared as described previously (16). Expression of
transfected genes was confirmed by Western blot analysis with a
polyclonal antibody to TIMP-3 (a kind gift of Suneel Apte, Cleveland,
OH) or monoclonal anti-FLAG (M2) antibody (Sigma).
Preparation of ECM--
Cells were plated onto six-well
culture plates (Costar). When confluent, the cells were removed from
the culture dishes following a 15-min incubation in Ca2+-,
Mg2+-free phosphate-buffered saline (PBS) containing 5 mM EGTA and 1 mM phenylmethylsulfonyl fluoride.
After several rinses in PBS and water the ECM was scraped in a small
volume of electrophoresis sample buffer without reducing agent. For
protein estimations, ECM was scraped in PBS containing 1 mM
phenylmethylsulfonyl fluoride. Protein concentrations were estimated
using the Bio-Rad protein assay reagent.
Zymography and Reverse Zymography--
Equal amounts of protein
were loaded on a 7.5% polyacrylamide gel with 1 mg/ml gelatin for
zymography or a 12% gel with 1 mg/ml gelatin plus baby hamster
kidney cell-conditioned medium as a source of MMPs for
reverse zymography. Following electrophoresis, gels were processed as
described previously (16). Briefly, gels were agitated in a solution of
25 mg/ml Triton X-100 to remove SDS and to promote renaturation of
proteases and inhibitors. The Triton was washed off with water, and the
gels were then incubated for 16 h in 50 mM Tris-HCl
(pH 7.5) containing 5 mM CaCl2 and 0.2 mg/ml
sodium azide at 37 °C. Gels were stained with 5 mg/ml Coomassie Blue
R-250 in acetic acid/methanol/water (1:3:6) for 2 h and destained
with acetic acid/methanol/water (1:3:6). Gelatinase activity was also
determined using a gelatinase activity assay kit (Chemicon
International, Temecula, CA) according to the manufacturer's instructions.
Cell Adhesion Assays--
Human laminin (Collaborative
Biomedical Inc., Bedford, MA) was immobilized on 96-well nontissue
culture-treated plates. Wells were washed and incubated with 3% bovine
serum albumin in PBS for 1 h at 37 °C. Subconfluent RPE cells
were harvested, washed, resuspended in culture medium (1 × 105 cells/ml) and allowed to attach to the wells for 30 min
at 37 °C. Nonadherent cells were removed by washing, and the
attached cells were stained for 10 min with crystal violet. The wells
were washed three times with PBS, and cell associated crystal violet was eluted by addition of 100 µl of 10% acetic acid. Cell adhesion was quantified by measuring the optical density of eluted crystal violet at a wavelength of 600 nm.
Cell Migration Assay--
A modified Boyden chamber assay was
carried out as described previously (17). 8.0-µm pore
polyvinylpyrrolidone-free polycarbonate membranes were precoated
with collagen type I (100 µg/ml). For migration of RPE cell
transfectants, laminin (5 µg/ml) or 10% fetal bovine serum was
placed in the lower wells, and RPE cells (1.0 × 105)
were placed in the upper wells. For endothelial cell chemotaxis, human
dermal microvascular endothelial cells (Clonetics, San Diego, CA)
(3.0 × 105) were placed in the upper wells and
allowed to migrate toward conditioned medium placed in the lower wells.
Chambers were incubated for 4 h at 37 °C in a 5%
CO2 humidified incubator. Cells remaining on the top of the
filter were removed. The bottom surface of the filter was fixed,
stained, and mounted. The number of cells migrating per well was
counted microscopically, and mean ± S.E. was calculated from
quadruplicate samples.
Matrigel and Type I Collagen Gel Invasion Assay--
This assay
was carried out as described previously (18) with some modifications.
Boyden chambers were used, and 8.0-µm
polyvinylpyrrolidone-free filters were coated with matrigel or
collagen type I gel (Collaborative Biomedical Inc.). The assay was
carried out at 37 °C for 18-24 h, and filters were fixed, stained,
and mounted. Invaded cells were counted under a microscope, and mean ± S.E. was calculated from quadruplicate samples.
Endothelial Cell Proliferation Assay--
This assay was carried
out as described previously (17). Human dermal microvascular
endothelial cells were incubated for 72 h in the presence of
conditioned medium from RPE cell transfectants. Cells were trypsinized
and counted using a Coulter particle counter.
Chick Chorioallantoic Membrane (CAM) Assays--
The CAM assay
was performed as described previously (19) with slight modifications.
Fertilized 3-day-old White Leghorn eggs (Sunnyside Inc., Beaver Dam,
WI) were cracked, and embryos with the yolk intact were placed
in 100- × 20-mm glass bottom Petri dishes. After incubation for 3 days
at 37 °C in 3% CO2, CAMs were implanted with 5-mm
diameter sterilized gelatin sponges (Gelfoam, Upjohn Co., Kalamazoo,
MI) loaded with equal protein amounts of conditioned medium from
RPE cell transfectants and photographed on day 3. CAMs implanted with
sponges loaded with serum-free medium alone or with basic fibroblast
growth factor or vascular endothelial growth factor were used as
negative and positive controls, respectively. Recombinant TIMP-3 (a
kind gift of Gillian Murphy, University of East Anglia,
United Kingdom) was added to some pellets. Samples were always compared
on the same CAM to avoid egg to egg variability. Responses were graded
as >, =, or < by independent readers.
SFD Mutant (S156C) TIMP-3 Protein Expressed in Human RPE Cells Is
an Inefficient TIMP--
To mimic the RPE cells in SFD, we generated
stable human RPE cell lines expressing WT or mutant (S156C)
Timp-3. The stable expression of protein was confirmed by
Western blot analysis using polyclonal antibodies to TIMP-3 (Fig.
1a) and was quantified by scanning densitometry (Fig. 1b). Like the endogenous TIMP-3
in RPE cells, both wild type and mutant forms of TIMP-3 were expressed predominantly in the ECM (Fig. 1, a and b) with a
small fraction being secreted into the conditioned medium (Fig. 1,
c and d). Wild type and mutant TIMP-3 proteins
were expressed at levels 3-5-fold over that of endogenous TIMP-3
present in ARPE-19 cells. Antibodies to the FLAG epitope also confirmed
the expression of these proteins in the ECM (Fig. 1e). MMP
inhibitory activity in the ECM of these cell lines was analyzed by
reverse zymography (Fig. 1f) and quantified by scanning
densitometry (Fig. 1, g and h). Mock-transfected
RPE cells (pcDNA3.1 alone) expressed endogenous functional TIMP-3
inhibitor in the ECM with an approximate molecular mass of 24 kDa
corresponding to the protein seen on Western blots (Fig. 1a)
as well as the 27 kDa glycosylated form (Fig. 1f). This inhibitory activity was increased in cells that were transfected with
the wild type Timp-3 construct. The glycosylated as well as
the nonglycosylated forms of mutant (S156C) TIMP-3 in the ECM demonstrated reduced MMP inhibitory activity when compared with WT-TIMP-3 (Fig. 1, g and h).
We hypothesized that a reduction in TIMP activity in the ECM of
RPE cells expressing mutant TIMP-3 may affect the protease activity secreted by these cells. Gelatin zymograms were used to test
the gelatinase activity in the conditioned medium, lysates, and ECM of
the transfected RPE cells. Endogenous 72-kDa gelatinase (pro-MMP-2)
activity was observed in the conditioned medium of mock-transfected RPE
cells (Fig. 2a). Densitometric
quantitation (data not shown) determined a marked increase in the
expression of this activity in the conditioned medium (60.4%) (Fig.
2a), cell lysates (57.2%) (Fig. 2c), and ECM
(72%) (Fig. 2e) of cells expressing S156C mutant TIMP-3.
Like other MMPs, gelatinase A is secreted as an inactive proenzyme, and
its cell-mediated activation requires binding of the C-terminal domain
of the proenzyme to a membrane-associated complex of the membrane-type
matrix metalloproteinase MT1-MMP and TIMP-2. Subsequent sequential
proteolysis of the propeptide by MT1-MMP and gelatinase A is believed
to generate the active form of gelatinase A, and this process can be
regulated by TIMP-2 or TIMP-3 (20). Concanavalin A (ConA) can induce
clustering of MT1-MMP, which plays a role in the activation of MMP-2 in
other systems (21). To study the potential role of mutant TIMP-3 in this process, RPE cells were treated with ConA, and the gelatinase activity in the conditioned medium (Fig. 2b) and cell
lysate/ECM (Fig. 2d) fractions were examined by gelatin
zymograms. RPE cells expressing mutant TIMP-3 showed an induction of
the active forms in the conditioned medium (62 and 43 kDa) and
lysate/ECM (62 kDa) (Fig. 2, b and d,
respectively). MMP-9 activity was observed only in the conditioned
medium of cells expressing mutant TIMP-3 (Fig. 2, a and
b). Active MMP-2 in the conditioned medium of these cells was also quantitated with a gelatinase activity assay utilizing a
biotinylated gelatinase substrate. This assay (Table
I) confirmed an increase in the
gelatinase activity in the conditioned medium of RPE cells expressing
S156C TIMP-3 in the absence or presence of ConA.
Thus, in terms of MMP activity, expression of S156C TIMP-3 in
RPE cells induced an increase in both pro-MMP-2 and active MMP-2 in the
conditioned medium, lysate, and ECM of the cells possibly as a result
of attenuated MMP inhibitory activity of the expressed mutant TIMP-3
protein. Since there is no decrease in the expression of MMP-2 in cells
overexpressing WT-TIMP-3, the possibility that the increase in MMP-2
activity in the cells expressing mutant TIMP-3 may be a direct
induction or activation of gelatinase A by the mutant TIMP-3
protein cannot be ruled out.
Expression of SFD Mutant (S156C) TIMP-3 Protein in RPE Cells
Results in Altered Cell Adhesion, Migration, and
Invasion--
Quiescent RPE cells rest on the inner aspect of Bruch's
membrane, which contains collagen type IV and laminin. MMPs play a key
role in the regulation of a variety of cellular functions. The adhesion
of RPE cells to ECM and the migratory and invasive properties of the
cell are critical for the maintenance of their physiological phenotype.
RPE cell attachment was measured on laminin (Fig.
3a). Overexpression of
WT-TIMP-3 had no effect on the adhesion of RPE cells to laminin
relative to the mock-transfected cells. However, expression of S156C
TIMP-3 resulted in a small but statistically significant decrease in
adhesion to laminin (Fig. 3a). Migration of S156C
TIMP-3-expressing RPE cells toward laminin (Fig. 3b) as well
as 10% fetal bovine serum (Fig. 3c) was significantly increased. Invasive capability of RPE cells through matrigel and collagen type I matrix revealed an increase in the invasive potential of RPE cells expressing S156C TIMP-3 (Fig. 3, d and
e, respectively). Overexpression of WT-TIMP-3 resulted in a
slight decrease in invasion through both matrigel and the collagen
matrix. Thus, expression of S156C TIMP-3 in the RPE resulted in
attenuated adhesion to ECM with a concomitant increase in the migratory
and invasive potential.
S156C TIMP-3 Mutation Induces Angiogenic Potential in RPE
Cells--
Choroidal neovascularization (CNV) is a major complication
of Sorsby's fundus dystrophy. RPE cells are believed to play a key
role in the pathogenesis of CNV (22-24). Therefore, we tested the
angiogenic potential of RPE cells expressing the S156C TIMP-3 mutation.
We first examined the ability of the conditioned medium of RPE cells to
induce migration and proliferation of endothelial cells. Conditioned
medium from RPE cells expressing S156C TIMP-3 increased the migration
of microvascular endothelial cells when compared with mock-transfected
as well as WT-TIMP-3-expressing RPE cells (Fig.
4a) but had no effect on their
proliferation (Fig. 4b). We also evaluated the effects of
the conditioned medium on angiogenesis using the CAM assay.
Interestingly conditioned medium from cells expressing S156C TIMP-3
showed an increase in the neovascularization response compared with
that induced by WT-TIMP-3 (in 89% of the CAMs tested,
n = 18) and control transfected cells (in 65% of the
CAMs tested, n = 17) (Fig. 4, c,
d, and e). Addition of recombinant human TIMP-3
to the S156C TIMP-3-conditioned medium inhibited the angiogenic
response (Fig. 4f). These results are consistent with the
data obtained from the migration experiments and suggest that the SFD
mutant (S156C TIMP-3) induces a proangiogenic phenotype in RPE
cells.
The RPE is believed to play a modulating role in the maintenance
of a vascularized and highly permeable fenestrated choriocapillaris on
its outer basal side. In vivo studies as well as clinical
observations have determined that the absence of RPE can lead to
secondary atrophy of the choriocapillaris (25-27). Polarized secretion
of vascular endothelial growth factor by the RPE toward the basal surface where its receptor KDR (vascular endothelial growth factor receptor-2) is localized on the inner choriocapillaris suggests a
possible mechanism for trophic paracrine signaling between RPE and
choriocapillaris (28). CNV is an important pathological feature of eye
diseases such as Sorsby's fundus dystrophy and the more common
age-related macular degeneration. During the course of CNV,
encapsulation of growing vessels by RPE coincides with the stasis of
further vascular growth (29). This suggests that the RPE might play a
critical role in controlling the initiation and progression of CNV.
A precise spatial and temporal regulation of extracellular proteolysis
is required for neovascularization. Recent studies have indicated that
members of the MMP family play an important role in angiogenesis
(30-33). Mice deficient in MMP-2 and MMP-9 exhibit reduced
angiogenesis in vivo (34, 35). MMP-2 is the most widely
distributed MMP and is localized on the surface of angiogenic blood
vessels (36). TIMP-3, a regulator of MMPs, is deposited by RPE cells
into Bruch's membrane where it is a component of ECM (8, 37). We have
previously demonstrated that TIMP-3 is a potent inhibitor of
angiogenesis (17). Since CNV is a prominent feature of SFD, with
accumulation of TIMP-3 deposits in Bruch's membrane (7), we
proposed to examine the mechanisms by which mutations in the TIMP-3
gene lead to the characteristic ocular phenotype (38, 39).
Expression of S156C TIMP-3 in human RPE cells results in a
reduction of MMP inhibitory (TIMP) activity in the ECM. Recombinant S156C TIMP-3 generated in NSO myeloma cells has association rate constants for a range of MMPs that are 2-3-fold reduced compared with
wild type TIMP-3 (40). However, the decrease in TIMP activity in RPE
cells is in contrast to that reported previously with expression in
COS-7 and baby hamster kidney cells (10, 40). In both of these cell
types, high levels of expression of mutant TIMP-3 protein gives rise to
dimers, which are not present in our study with RPE cells. We expressed
protein at relatively low levels in cells that expressed endogenous
wild type protein to mimic the heterozygous autosomal dominant
phenotype. That TIMP-3 functions may be cell type-specific has been
recently suggested with the observation that TIMP-3 may have
antiapoptotic activity and is a critical survival factor during mammary
gland involution (38). This is in contrast to several reports that
demonstrate that high levels of TIMP-3 are proapoptotic in both normal
and cancer cell lines (41-46). In our studies with RPE cells,
overexpression of TIMP-3 at modest levels does not affect cell survival
(data not shown). Thus the divergent effects of TIMP-3 on cell survival
as well as its other potential functions may depend on the cell type, microenvironment, and amount of TIMP-3 in the microenvironment (38).
This might also explain the exclusive ocular phenotype seen in patients
with the SFD mutation.
Constitutive activation of gelatinase A was observed in the conditioned
medium and ECM of RPE cells expressing S156C TIMP-3. This was not
surprising given the finding that SFD mutant TIMP-3 was an inefficient
MMP inhibitor. Unscheduled MMP-2 activation was also observed in
the lungs and mammary glands of homozygous Timp-3-null mice
(38, 39). It has been hypothesized that, under normal physiological
conditions, choroidal endothelial cells are maintained in a quiescent
state because of an orchestrated balance between angiogenic inducers
and inhibitors. WT-TIMP-3 deposited by RPE cells into Bruch's membrane
efficiently inhibits neovascular invasion from the choriocapillaris by
inhibiting MMP activity, resulting in an intact matrix, and/or binding
directly to the surface of endothelial cells to inhibit endothelial
cell responses. Our results suggest that, during pathological CNV as seen in SFD, expression of mutant TIMP-3 in RPE cells may result in an
accentuation of MMP activity, which can contribute to an angiostimulatory phenotype. While it is clear that endothelial cell
basement membrane degradation is critical for angiogenesis, very little
is known about the basic mechanism responsible for this process. There
are several possibilities. Intact matrix might provide a physical
barrier that limits endothelial cell migration and invasion into the
surrounding ECM. Breakdown of the basement membrane allows the
endothelial cells to initiate the process of sprouting. Alternatively
proteolysis of ECM may release sequestered angiogenic factors such as
vascular endothelial growth factor and/or basic fibroblast growth
factor, which promote endothelial cell proliferation and migration.
Finally a third possibility that has been recently proposed is the
exposure of an angiogenic cryptic site upon proteolytic cleavage of ECM
molecules such as collagen type IV (9).
In this study we show that the CNV phenotype seen in SFD may be a
result of reduced MMP inhibitory activity with a concomitant increase
in MMP-2 activity. This appears to provide the cells with the ability
to induce angiogenesis as shown by both in vitro and
in vivo assays. These results might explain the
pathophysiological mechanism of CNV in SFD and suggest the potential
use of MMP inhibitors locally in the subretinal space as a means of therapy.
We thank Jim Lang for photography and
Suneel Apte for critical reading of the manuscript. We extend a sincere
apology to colleagues whose work was not cited because of space limitations.
*
This work was supported by National Institutes of Health
Grant 1 R29 EY12109-01, a Foundation Fighting Blindness module grant, and a Cleveland Clinic Foundation seed grant (to B. A.-A.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, January 30, 2002, DOI 10.1074/jbc.M110870200
The abbreviations used are:
SFD, Sorsby's
fundus dystrophy;
TIMP, tissue inhibitor of metalloproteinase;
MMP, matrix metalloproteinase;
CAM, chorioallantoic membrane;
RPE, retinal
pigment epithelium;
ECM, extracellular matrix;
PBS, phosphate-buffered
saline;
ConA, concanavalin A;
MT, membrane-type;
CNV, choroidal
neovascularization;
CM, conditioned medium.
Expression of Sorsby's Fundus Dystrophy Mutations in Human
Retinal Pigment Epithelial Cells Reduces Matrix Metalloproteinase
Inhibition and May Promote Angiogenesis*
,
,
¶
Department of Ophthalmic Research, Cole Eye
Institute and the ¶ Department of Cell Biology, Lerner
Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195 and the § School of Biological Sciences, University of East
Anglia, Norwich NR47TJ, United Kingdom
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (88K):
[in a new window]
Fig. 1.
Analysis of WT-Timp-3-
(WT-1 and WT-5),
S156C-Timp-3-
(156-1 and
156-3), and vector alone
(C1 and C3)-transfected ARPE-19
cells. Shown are the TIMP-3 immunoblots of ECM
(a) and conditioned medium (c) with corresponding
densitometry quantitation (b and d,
respectively). e, FLAG immunoblot analysis of ECM. Reverse
zymographic analysis of ECM (f) with corresponding
densitometric quantitation of the 24-kDa band (g) and
glycosylated 27-kDa band (h) is shown. Data are
representative of two separate experiments. Densitometry results are
expressed as arbitrary OD units ± S.D.

View larger version (46K):
[in a new window]
Fig. 2.
Zymographic analyses of
WT-Timp-3- (WT-1 and
WT-5), S156C-Timp-3-
(156-1 and
156-3), and vector alone
(C1 and C3)-transfected ARPE-19
cells. Conditioned medium (a), lysate
(c), and ECM (e) are shown with corresponding
analyses of ConA-treated samples (b and d,
respectively). Results are representative of three independent
experiments.
Secretion of active MMP-2 by transfected ARPE-19 cells

View larger version (37K):
[in a new window]
Fig. 3.
Adhesion, migration, and invasion of
WT-Timp-3- (WT-1 and
WT-5), S156C-Timp-3-
(156-1 and
156-3), and vector alone
(C1 and C3)-transfected ARPE-19
cells. a, adhesion of transfected cells on
laminin; b and c, migration of RPE transfectants
toward laminin (b) and 10% fetal bovine serum
(c). d and e, invasion of RPE
transfectants through matrigel (d) and collagen type I
(e). Data are expressed as the mean of
triplicate samples ± S.D. and are representative
of two independent experiments.

View larger version (119K):
[in a new window]
Fig. 4.
Angiogenic potential of conditioned medium
(CM) of WT-Timp-3- (WT-1 and
WT-5), S156C-Timp-3- (156-1 and 156-3), and vector alone
(C1 and C3)-transfected ARPE-19
cells. a, endothelial cell migration;
b, endothelial cell proliferation; c,
CAM assay (vector control CM); d, CAM assay
(WT-Timp-3 CM); e, CAM assay
(S156C-Timp-3 CM); f, CAM assay
(S156C-Timp-3 CM + recombinant human TIMP-3, 2.5 µg).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
To whom correspondence should be addressed: Dept. of
Ophthalmic Research, Cole Eye Inst./I-131, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195. E-mail:
anandab@ccf.org.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Sorsby, A., and Joll Mason, M. E. (1949) Br. J. Ophthalmol. 67-97
2.
Holz, F. G.,
Haimovici, R.,
Wagner, D. G.,
and Bird, A. C.
(1994)
Retina
14,
329-334[CrossRef][Medline]
[Order article via Infotrieve] 3.
Jacobson, S. G.,
Cideciyan, A. V.,
Regunath, G.,
Rodriguez, F. J.,
Vandenburgh, K.,
Sheffield, V. C.,
and Stone, E. M.
(1995)
Nat. Genet.
11,
27-32[CrossRef][Medline]
[Order article via Infotrieve] 4.
Kalmus, H.,
and Seedburgh, D.
(1976)
J. Med. Genet.
13,
271-276 5.
Polkinghorne, P. J.,
Capon, M. R.,
Berninger, T.,
Lyness, A. L.,
Sehmi, K.,
and Bird, A. C.
(1989)
Ophthalmology
96,
1763-1768[Medline]
[Order article via Infotrieve] 6.
Capon, M. R.,
Marshall, J.,
Krafft, J. I.,
Alexander, R. A.,
Hiscott, P. S.,
and Bird, A. C.
(1989)
Ophthalmology
96,
1769-1777[Medline]
[Order article via Infotrieve] 7.
Fariss, R. N.,
Apte, S. S.,
Luthert, P. J.,
Bird, A. C.,
and Milam, A. H.
(1998)
Br. J. Ophthalmol.
82,
1329-1334 8.
Kamei, M.,
and Hollyfield, J.
(1999)
Investig. Ophthalmol. Vis. Sci.
40,
2367-2375 9.
Xu, J.,
Rodriguez, D.,
Petitclerc, E.,
Kim, J. J.,
Hangai, M.,
Yuen, S. M.,
Davis, G. E.,
and Brooks, P. C.
(2001)
J. Cell Biol.
154,
1069-1080 10.
Langton, K. P.,
McKie, N.,
Curtis, A.,
Goodship, J. A.,
Bond, P. M.,
Barker, M. D.,
and Clarke, M.
(2000)
J. Biol. Chem.
275,
27027-27031 11.
Tabata, Y.,
Isashiki, Y.,
Kamimura, K.,
Nakao, K.,
and Ohba, N.
(1998)
Hum. Genet.
103,
179-182[Medline]
[Order article via Infotrieve] 12.
Weber, B. H.,
Vogt, G.,
Pruett, R. C.,
Stohr, H.,
and Felbor, U.
(1994)
Nat. Genet.
8,
352-356[CrossRef][Medline]
[Order article via Infotrieve] 13.
Woessner, J. F., Jr.
(2001)
J. Clin. Investig.
108,
799-800[CrossRef][Medline]
[Order article via Infotrieve] 14.
Langton, K. P.,
Barker, M. D.,
and McKie, N.
(1998)
J. Biol. Chem.
273,
16778-16781 15.
Yu, W. H., Yu, S.,
Meng, Q.,
Brew, K.,
and Woessner, J. F., Jr.
(2000)
J. Biol. Chem.
275,
31226-31232 16.
Pavloff, N.,
Staskus, P. W.,
Kishnani, N. S.,
and Hawkes, S. P.
(1992)
J. Biol. Chem.
267,
17321-17326 17.
Anand-Apte, B.,
Pepper, M. S.,
Voest, E.,
Montesano, R.,
Olsen, B.,
Murphy, G.,
Apte, S. S.,
and Zetter, B.
(1997)
Investig. Ophthalmol. Vis. Sci.
38,
817-823 18.
Banyard, J.,
Anand-Apte, B.,
Symons, M.,
and Zetter, B. R.
(2000)
Oncogene
19,
580-591[CrossRef][Medline]
[Order article via Infotrieve] 19.
Nguyen, M.,
Shing, Y.,
and Folkman, J.
(1994)
Microvasc. Res.
47,
31-40[CrossRef][Medline]
[Order article via Infotrieve] 20.
Will, H.,
Atkinson, S. J.,
Butler, G. S.,
Smith, B.,
and Murphy, G.
(1996)
J. Biol. Chem.
271,
17119-17123 21.
Yu, M.,
Sato, H.,
Seiki, M.,
and Thompson, E. W.
(1995)
Cancer Res.
55,
3272-3277 22.
D'Amore, P. A.
(1994)
Investig. Ophthalmol. Vis. Sci.
35,
3974-3979 23.
Campochiaro, P. A.
(1999)
Mol. Vis.
5,
24[Medline]
[Order article via Infotrieve] 24.
Campochiaro, P. A.
(2000)
J. Cell. Physiol.
184,
301-310[CrossRef][Medline]
[Order article via Infotrieve] 25.
Korte, G. E.,
Gerszberg, T.,
Pua, F.,
and Henkind, P.
(1986)
Acta Anat. (Basel)
127,
171-175[Medline]
[Order article via Infotrieve] 26.
Sakamoto, T.,
Sakamoto, H.,
Hinton, D. R.,
Spee, C.,
Ishibashi, T.,
and Ryan, S. J.
(1995)
Curr. Eye Res.
14,
621-627[Medline]
[Order article via Infotrieve] 27.
Sakamoto, T.,
Sakamoto, H.,
Murphy, T. L.,
Spee, C.,
Soriano, D.,
Ishibashi, T.,
Hinton, D. R.,
and Ryan, S. J.
(1995)
Arch. Ophthalmol.
113,
512-520[Medline]
[Order article via Infotrieve] 28.
Blaauwgeers, H. G.,
Holtkamp, G. M.,
Rutten, H.,
Witmer, A. N.,
Koolwijk, P.,
Partanen, T. A.,
Alitalo, K.,
Kroon, M. E.,
Kijlstra, A.,
van Hinsbergh, V. W.,
and Schlingemann, R. O.
(1999)
Am. J. Pathol.
155,
421-428 29.
Miller, H.,
Miller, B.,
and Ryan, S. J.
(1986)
Investig. Ophthalmol. Vis. Sci.
27,
1644-1652 30.
Hiraoka, N.,
Allen, E.,
Apel, I. J.,
Gyetko, M. R.,
and Weiss, S. J.
(1998)
Cell
95,
365-377[CrossRef][Medline]
[Order article via Infotrieve] 31.
Stetler-Stevenson, W. G.,
and Yu, A. E.
(2001)
Semin. Cancer Biol.
11,
143-152[CrossRef][Medline]
[Order article via Infotrieve] 32.
Stetler-Stevenson, W. G.
(2001)
Surg. Oncol. Clin. N. Am.
10,
383-392[Medline]
[Order article via Infotrieve] 33.
Werb, Z., Vu, T. H.,
Rinkenberger, J. L.,
and Coussens, L. M.
(1999)
APMIS
107,
11-18[Medline]
[Order article via Infotrieve] 34.
Itoh, T.,
Tanioka, M.,
Yoshida, H.,
Yoshioka, T.,
Nishimoto, H.,
Itohara, S.,
Hofman, P.,
van Blijswijk, B. C.,
Gaillard, P. J.,
Vrensen, G. F.,
and Schlingemann, R. O.
(1998)
Cancer Res.
58,
1048-1051 35.
Vu, T. H.,
Shipley, J. M.,
Bergers, G.,
Berger, J. E.,
Helms, J. A.,
Hanahan, D.,
Shapiro, S. D.,
Senior, R. M.,
and Werb, Z.
(1998)
Cell
93,
411-422[CrossRef][Medline]
[Order article via Infotrieve] 36.
Brooks, P. C.
(1996)
Cancer Metastasis Rev.
15,
187-194[CrossRef][Medline]
[Order article via Infotrieve] 37.
Fariss, R. N.,
Apte, S. S.,
Olsen, B. R.,
Iwata, K.,
and Milam, A. H.
(1997)
Am. J. Pathol.
150,
323-328[Abstract] 38.
Fata, J. E.,
Leco, K. J.,
Voura, E. B., Yu, H. Y.,
Waterhouse, P.,
Murphy, G.,
Moorehead, R. A.,
and Khokha, R.
(2001)
J. Clin. Investig.
108,
831-841[CrossRef][Medline]
[Order article via Infotrieve] 39.
Leco, K. J.,
Waterhouse, P.,
Sanchez, O. H.,
Gowing, K. L.,
Poole, A. R.,
Wakeham, A.,
Mak, T. W.,
and Khokha, R.
(2001)
J. Clin. Investig.
108,
817-829[CrossRef][Medline]
[Order article via Infotrieve] 40.
Yeow, K. M.,
Kishnani, N. S.,
Hutton, M.,
Hawkes, S. P.,
Murphy, G.,
and Edwards, D. R.
(2002)
Matrix Biol.
21,
75-88[CrossRef][Medline]
[Order article via Infotrieve] 41.
Baker, A. H.,
George, S. J.,
Zaltsman, A. B.,
Murphy, G.,
and Newby, A. C.
(1999)
Br. J. Cancer
79,
1347-1355[CrossRef][Medline]
[Order article via Infotrieve] 42.
Baker, A. H.,
Zaltsman, A. B.,
George, S. J.,
and Newby, A. C.
(1998)
J. Clin. Investig.
101,
1478-1487[Medline]
[Order article via Infotrieve] 43.
Bond, M.,
Murphy, G.,
Bennett, M. R.,
Amour, A.,
Knauper, V.,
Newby, A. C.,
and Baker, A. H.
(2000)
J. Biol. Chem.
275,
41358-41363 44.
Ahonen, M.,
Baker, A. H.,
and Kahari, V. M.
(1998)
Adv. Exp. Med. Biol.
451,
69-72[Medline]
[Order article via Infotrieve] 45.
Ahonen, M.,
Baker, A. H.,
and Kahari, V. M.
(1998)
Cancer Res.
58,
2310-2315 46.
George, S. J.,
Lloyd, C. T.,
Angelini, G. D.,
Newby, A. C.,
and Baker, A. H.
(2000)
Circulation
101,
296-304
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J. Verstappen and J.W. Von den Hoff Tissue Inhibitors of Metalloproteinases (TIMPs): Their Biological Functions and Involvement in Oral Disease. J. Dent. Res., December 1, 2006; 85(12): 1074 - 1084. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Shu, B. Tulloch, A. Lennon, D. Vlachantoni, X. Zhou, C. Hayward, and A. F. Wright Disease mechanisms in late-onset retinal macular degeneration associated with mutation in C1QTNF5 Hum. Mol. Genet., May 15, 2006; 15(10): 1680 - 1689. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. P. Langton, N. McKie, B. M. Smith, N. J. Brown, and M. D. Barker Sorsby's fundus dystrophy mutations impair turnover of TIMP-3 by retinal pigment epithelial cells Hum. Mol. Genet., December 1, 2005; 14(23): 3579 - 3586. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Strauss The Retinal Pigment Epithelium in Visual Function Physiol Rev, July 1, 2005; 85(3): 845 - 881. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Klenotic, F. L. Munier, L. Y. Marmorstein, and B. Anand-Apte Tissue Inhibitor of Metalloproteinases-3 (TIMP-3) Is a Binding Partner of Epithelial Growth Factor-containing Fibulin-like Extracellular Matrix Protein 1 (EFEMP1): IMPLICATIONS FOR MACULAR DEGENERATIONS J. Biol. Chem., July 16, 2004; 279(29): 30469 - 30473. [Abstract] [Full Text] [PDF] |
||||
![]() |
G McGwin Jr, C Owsley, C A Curcio, and R J Crain The association between statin use and age related maculopathy Br. J. Ophthalmol., September 1, 2003; 87(9): 1121 - 1125. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Visse and H. Nagase Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry Circ. Res., May 2, 2003; 92(8): 827 - 839. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||